JO
CRL icon

John Overdeck’s Charles River Laboratories CRL Stock Holding History

John Overdeck’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,600
Closed -$2.86M – 2990
2021
Q4 		$2.86M Buy
7,600
+6,700
+744% +$2.6M 0.01% 1609
2021
Q3 		$371K Buy
+900
New +$374K ﹤0.01% 3502

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

John Overdeck's CRL Position: Q2 2026 in Review

John Overdeck sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 20,623 shares — an estimated $3.56M sold.

John Overdeck first reported a position in CRL in Q2 2013 and held it in 44 quarters. The position peaked at $74.1M in Q1 2022. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • John Overdeck reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 20,623 Charles River Laboratories shares in Q2 2026, an estimated $3.56M.
  • John Overdeck first reported a position in Charles River Laboratories in Q2 2013 and held it in 44 quarters.
  • John Overdeck's Charles River Laboratories position peaked at $74.1M in Q1 2022.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.